Want to see PROK full AI Analyst Report?
PROK Stock Chart & Stats
$1.73
-$0.02(-1.32%)
At close: 4:00 PM EDT
$1.73
-$0.02(-1.32%)
Day’s Range― - ―
52-Week Range$1.30 - $3.48
Previous CloseN/A
Volume1.72M
Average Volume (3M)1.45M
Market Cap
$483.72M
Enterprise Value$1.31K
Total Cash (Recent Filing)$181.56M
Total Debt (Recent Filing)$3.52M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Nov 16, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding208,926,940
10 Day Avg. Volume2,107,034
30 Day Avg. Volume1,452,359
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.75Price Target Upside232.37% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$485.71K
Bulls Say, Bears Say
Bulls Say
Lead Therapy And Focused IndicationA focused lead program addressing chronic kidney disease gives ProKidney a clear development strategy and a defined patient population. If rilparencel demonstrates durable kidney-function preservation, the therapy could support a differentiated commercial opportunity in a serious, chronic condition with substantial treatment needs.
Phase 3 And Regulatory ProgressProgress in the pivotal Phase 3 program, together with FDA alignment on eGFR slope as a surrogate endpoint, may reduce regulatory uncertainty and clarify the approval path. This strengthens the development program’s strategic value over the next several quarters, subject to clinical results.
Low Reported DebtVery low reported debt limits direct leverage pressure and reduces the burden of interest and refinancing obligations. Although the company remains dependent on external capital because of its cash burn, a lightly indebted structure provides more flexibility than a heavily leveraged balance sheet during clinical development.
Bears Say
Heavy Ongoing Cash BurnThe scale of operating and free-cash-flow outflows shows that ProKidney is not self-funding its development activities. Continued cash consumption increases reliance on external financing, which can constrain strategic flexibility and create dilution or funding pressure while pivotal trials and manufacturing development continue.
Minimal Revenue And Large LossesMinimal, volatile revenue provides little evidence of current commercial scale, while losses remain extremely large relative to sales. Until rilparencel is approved and commercialized, the company lacks an established recurring revenue base to offset research, clinical, and development expenditures.
Persistent Negative EquityNegative equity over several annual periods indicates accumulated deficits or capital-structure complexity rather than a balance sheet supported by retained earnings. This weakens financial resilience and reinforces the need for successful clinical execution and continued access to capital to sustain operations.
ProKidney News
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $1.30 and its highest was $3.48 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $483.72M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Nov 16, 2026 which is in 49 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Aug 10, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.01.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -0.15.
How many shares outstanding does ProKidney have?
ProKidney has 208,926,940 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went down -4.734%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.75 (232.37% Upside)
$5.75 (232.37% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 582.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProKidney
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.75
▲(232.37% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
46.34% Insiders
1.95% Mutual Funds
8.52% Other Institutional Investors
39.58% Public Companies and
Individual Investors